Enzyme immobilization
A free enzyme works once. An immobilised enzyme can be recovered, reused and run in continuous — which is usually what decides whether a biocatalytic step is affordable at production scale. We develop the immobilisation, then we prove it holds up over cycles.
Talk to us about your processThe economics of a biocatalytic step
Immobilisation is rarely about the chemistry alone. It is about what the enzyme costs you per kilogram of product, and about what the reactor can do once the biocatalyst stays put.
Reuse
The biocatalyst is recovered at the end of the batch and put back in. The cost of the enzyme is divided across the number of cycles it survives — which is why operational stability, not initial activity, is the number that matters.
Continuous operation
An immobilised enzyme can be packed in a column and fed continuously. It changes the plant, not just the step: smaller reactors, steadier output, less handling.
A cleaner downstream
The enzyme does not end up in the product stream. No protein to remove, no denaturation step, and a simpler purification behind it.
The biocatalytic steps with the greatest impact in pharma
- Stereoselective reductions: ketones reduced with ketoreductases and alcohol dehydrogenases, with cofactor regeneration: chiral alcohols for APIs and intermediates.
- Transaminations: ω-transaminases for chiral amines from the corresponding ketones.
- Kinetic resolutions and desymmetrisations: lipases and esterases for enantiopure alcohols, acids and esters.
- Selective oxidations: oxygen-dependent enzymes, monooxygenases and oxidases, flow reactors included.
- Amides and nitriles: acylases, amidases, nitrilases and nitrile hydratases.
- Integrated chemo-enzymatic processes: the enzymatic step built into the chemical synthesis, in place of one or more steps with protection and deprotection.
How a project runs
Three stages, each with its own decision point. How long each one takes depends on the complexity of the reaction — we size it after the first conversation, not before.
Proof of concept
Does this enzyme immobilise at all, and does it keep enough activity to be worth it? We screen carriers and coupling chemistries in parallel and measure the activity recovered on each. The output is a shortlist and an honest answer, including when the answer is no.
Optimisation
On the carriers that survived: loading, coupling conditions, buffer and pH, particle size, and the reaction conditions around them. Here we build the reuse curve — how many cycles before the activity drops below what your process can accept.
Industrialisation
Scale, cost per kilogram of biocatalyst, reproducibility batch to batch, and behaviour in the real matrix rather than in a clean buffer. This is where a promising lab result either becomes a process or shows why it will not.
What we measure
Immobilisation is easy to claim and easy to get wrong. These are the endpoints we report, and the ones we would ask for if we were on your side of the table.
- Activity recovered — units retained on the carrier against the free enzyme charged
- Immobilisation yield — how much of the protein actually bound, and how much stayed in solution
- Operational stability — the reuse curve, cycle by cycle, to the point where activity falls below threshold
- Leaching — protein released into the product stream over the cycles
- Kinetics on the carrier — apparent Km and diffusional limits, which is where a good enzyme becomes a slow one
- Thermal and pH window — how the immobilised form differs from the free one, which is often the real gain
- Behaviour in the real matrix — with your substrate and your impurities, not in clean buffer
- Batch-to-batch reproducibility — the same preparation, repeated, with the spread declared
On the client’s carrier, with the numbers in hand
We also work on the carrier the client chooses, and measure residual activity per cycle down to the break-even threshold. Cost per kilogram is calculated after screening against the process in use: biocatalyst and number of cycles, solvent and recovery, downstream separations, energy. Every stage has go/no-go criteria stated before it starts.
Not every enzyme should be immobilised: for some steps, free enzyme dosed in line is the most economical choice, and we show it with data. For immobilised enzymes we measure stability over use and cleaning cycles of the carrier, and we prepare the data for transfer to the engineering company that will build the continuous line.
The laboratory behind it
Equipment
| Reaction | Stirred tank and fixed bed reactors, for batch and continuous operation, at laboratory and pilot scale |
| Immobilisation | Screening of carriers and coupling chemistries, loading trials and reuse cycles |
| Biocatalyst recovery | Ultrafiltration and tangential flow filtration, to separate it and put it back in cycle |
| Analytics | HPLC and UPLC, gas chromatography, spectrophotometry and enzymatic assays |
What you take away
| Biocatalyst | The immobilised preparation itself, in the quantity the stage requires |
| Dossier | Data, conditions tested and results, in the form your technical file needs |
| Pilot batch | Production at scale when the project reaches that point |
Start with the reaction
Tell us the enzyme, the substrate and the scale you are aiming at. We will tell you whether immobilisation is the right move, and what the first stage would look like.
Talk to us about your process